MG
MEDP icon

Michael Gelband’s Medpace MEDP Stock Holding History

Michael Gelband’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,741
Closed -$1.54M – 1883
2025
Q4 		$1.54M Buy
+2,741
New +$1.56M 0.01% 849
2023
Q4 		– Sell
-3,462
Closed -$838K – 1822
2023
Q3 		$838K Sell
3,462
-9,940
-74% -$2.54M 0.01% 1020
2023
Q2 		$3.22M Sell
13,402
-3,925
-23% -$815K 0.03% 606
2023
Q1 		$3.26M Buy
17,327
+6,530
+60% +$1.35M 0.03% 683
2022
Q4 		$2.29M Sell
10,797
-1,730
-14% -$346K 0.03% 583
2022
Q3 		$1.97M Buy
+12,527
New +$2M 0.03% 807
2022
Q2 		– Sell
-1,341
Closed -$219K – 2236
2022
Q1 		$219K Sell
1,341
-6,874
-84% -$1.13M ﹤0.01% 1878
2021
Q4 		$1.79M Buy
+8,215
New +$1.72M 0.02% 807
2020
Q4 		– Sell
-30,004
Closed -$3.35M – 2211
2020
Q3 		$3.35M Buy
+30,004
New +$3.47M 0.07% 255

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Michael Gelband's MEDP Position: Q1 2026 in Review

Michael Gelband sold out of Medpace (MEDP) in Q1 2026, closing a stake of 2,741 shares — an estimated $1.54M sold.

Michael Gelband first reported a position in MEDP in Q3 2020 and held it in 9 quarters. The position peaked at $3.35M in Q3 2020. 732 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

  • Michael Gelband reported no remaining Medpace position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 2,741 Medpace shares in Q1 2026, an estimated $1.54M.
  • Michael Gelband first reported a position in Medpace in Q3 2020 and held it in 9 quarters.
  • Michael Gelband's Medpace position peaked at $3.35M in Q3 2020.
  • 732 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.